Receptor tyrosine kinases (RTKs), such as HER-2, are also key factors involved in breast cancer chemoresistance through activation of the phosphoinositide 3-LKinase (PI3K)/protein kinase (AKT) signaling pathway. Here, ERBB2 is linked to breast carcinoma.